Atsena Selects Lead Candidate for Dual-Vector AAV Gene Therapy Program in Stargardt Disease
July 9, 2026 — Atsena Therapeutics announced the selection of a lead clinical candidate for ATSN-401, its investigational gene therapy program for Stargardt disease, the most common inherited macular…
Read the full articleYou might also wanna read
Apertura Enters CRADA with NIH Institutes to Evaluate BBB-Crossing AAV Capsid for NPC1 Gene Therapy
PackGene Biotech·1d ago
Allotera Therapeutics Raises Additional $35M to Advance Off-the-Shelf CAR-T Therapy for T-Cell Cancers
PackGene Biotech·2d ago
Genespire Reports Preclinical Data Supporting Immune-Shielded Lentiviral Gene Therapy for MMA
PackGene Biotech·2d ago
Engineered AAV5 Vectors Use Glymphatic Delivery to Target Human Glial Cells Across the Brain
PackGene Biotech·2d ago
Epicrispr Completes Dose Escalation in First-in-Human AAV Gene Therapy Trial for FSHD
PackGene Biotech·3d ago
FDA Clears IND for CoRegen’s CRISPR-Engineered Treg Cell Therapy in Advanced Solid Tumors
PackGene Biotech·3d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.